Rated 5 out of 5 Merrel A
A method of preventing gait abnormalities in a patient with Parkinson's disease or of improving or restoring to normal the gait of a patient with Parkinson's disease, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to prevent, improve or restore to normal said gait, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 where Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
Failed-COA batches always replaced
References to weight loss, weight reduction, or type 2 diabetes throughout this page describe areas of active scientific investigation and do not constitute treatment recommendations or clinical claims
69 Two 0.8 mm-diameter Kirschners wires were inserted percutaneously through the third and fifth coccygeal vertebrae
